{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:02:03Z","timestamp":1778914923136,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Evidence for the safe use of Lumason\u00ae (SonoVue\u00ae), an ultrasound enhancing agent (UEA), in special patient populations is critical to enable healthcare professionals to make informed decisions concerning its use in such patients. Herein, we provide insight on the safety and tolerability of Lumason\u00ae in special patient populations. Findings are presented from clinical pharmacology studies conducted in patients with compromised cardiopulmonary conditions, from a retrospective study performed in critically ill patients, and from post-marketing surveillance data from over 20 years of market use of Lumason\u00ae (SonoVue\u00ae). No detrimental effects of Lumason\u00ae on cardiac electrophysiology were observed in patients with coronary artery disease (CAD), and no significant effects on pulmonary hemodynamics were noted in patients with pulmonary hypertension or congestive heart failure. Similarly, no effects on several assessments of pulmonary function (e.g., FVC) were observed in patients with chronic obstructive pulmonary disease (COPD), and no clinically meaningful changes in O<jats:sub>2<\/jats:sub> saturation or other safety parameters were observed after administration of Lumason\u00ae to patients with diffuse interstitial pulmonary fibrosis (DIPF). The retrospective study of critically ill patients revealed no significant difference for in-hospital mortality between patients administered Lumason\u00ae for echocardiography versus those who had undergone echocardiography without contrast agent. Post-marketing surveillance revealed very low reporting rates (RR) for non-serious and serious adverse events and that serious hypersensitivity reactions were rare. These findings confirm that Lumason\u00ae is a safe and well tolerated UEA for use in special populations and critically ill patients.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1225654","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T09:47:18Z","timestamp":1690969638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety of Lumason\u00ae (SonoVue\u00ae) in special populations and critically ill patients"],"prefix":"10.3389","volume":"10","author":[{"given":"A.","family":"Filippone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Kirchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Monteith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Storto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.echo.2014.05.011","article-title":"Guidelines forthe cardiac sonographer in the performance of contrast echocardiography: a focused update from the American society of echocardiography","volume":"27","author":"Porter","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ultrasmedbio.2020.04.030","article-title":"Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS","volume":"46","author":"Dietrich","year":"2020","journal-title":"Ultrasound Med Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/hrt.2007.135145","article-title":"Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies","volume":"94","author":"Aggeli","year":"2008","journal-title":"Heart"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.amjcard.2008.06.066","article-title":"Safety of ultrasound contrast agents in stress echocardiography","volume":"102","author":"Gabriel","year":"2008","journal-title":"Am J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1001\/jama.299.17.2023","article-title":"Incidence of adverse events associated with use of perflutren contrast agents for echocardiography","volume":"299","author":"Herzog","year":"2008","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2008.03.006","article-title":"Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies","volume":"51","author":"Kusnetzky","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.amjcard.2008.08.019","article-title":"Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients)","volume":"102","author":"Main","year":"2008","journal-title":"Am J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.amjcard.2008.07.032","article-title":"Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress","volume":"102","author":"Shaikh","year":"2008","journal-title":"Am J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.echo.2008.07.019","article-title":"The safety of definity and optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses","volume":"21","author":"Wei","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jcmg.2009.03.020","article-title":"Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients","volume":"2","author":"Abdelmoneim","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjcard.2009.02.041","article-title":"Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin","volume":"104","author":"Anantharam","year":"2009","journal-title":"Am J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jacc.2008.08.066","article-title":"Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience","volume":"53","author":"Dolan","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCIMAGING.109.895029","article-title":"Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study","volume":"3","author":"Abdelmoneim","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jcmg.2010.04.006","article-title":"A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent","volume":"3","author":"Exuzides","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000338731","article-title":"Administration of perflutren contrast agents during transthoracic echocardiography is not associated with a significant increase in acute mortality risk","volume":"122","author":"Goldberg","year":"2012","journal-title":"Cardiology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.echo.2012.04.002","article-title":"CaRES (contrast echocardiography registry for safety surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice","volume":"25","author":"Weiss","year":"2012","journal-title":"J Am Soc Echocardiogr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ehjci\/jes057","article-title":"Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study","volume":"13","author":"Wever-Pinzon","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.hlc.2013.05.637","article-title":"The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort","volume":"22","author":"Platts","year":"2013","journal-title":"Heart Lung Circ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcmg.2013.08.012","article-title":"Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent","volume":"7","author":"Main","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.echo.2014.04.020","article-title":"An observational study of the occurrence of serious adverse reactions among patients who receive optison in routine medical practice","volume":"27","author":"Wei","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/CIRCULATIONAHA.108.831156","article-title":"Overview of the 2008 food and drug administration advisory committee on safety considerations in the development of ultrasound contrast agents","volume":"2009","author":"Asch","year":"","journal-title":"Circulation"},{"key":"B22","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.15420\/usc.2012.9.1.35","article-title":"The history of product label changes for DEFINITY in the United States","volume":"9","author":"Main","year":"2012","journal-title":"US Cardiology"},{"key":"B24","year":""},{"key":"B25","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.echo.2008.09.009","article-title":"American society of echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography","volume":"21","author":"Mulvagh","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.amjcard.2021.03.039","article-title":"Impact of contrast echocardiography on outcomes in critically ill patients","volume":"150","author":"Main","year":"2021","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2009.01.005","article-title":"Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort","volume":"53","author":"Kurt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cvr\/cvz013","article-title":"A current understanding of drug-induced QT prolongation and its implications for anticancer therapy","volume":"115","author":"Roden","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e005459","DOI":"10.1161\/CIRCIMAGING.116.005459","article-title":"Safety with echocardiographic contrast agents","volume":"10","author":"Muskula","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heart.84.6.634","article-title":"Safety of an intravenous second-generation contrast agent in patients with severe left ventricular dysfunction","volume":"84","author":"Soman","year":"2000","journal-title":"Heart"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/00004424-200102000-00006","article-title":"Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease","volume":"36","author":"Bokor","year":"2001","journal-title":"Invest Radiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/009286150003400106","article-title":"Contents and quality control of ambulatory electrocardiographic (Holter) reports and data","volume":"34","author":"Callahan","year":"2000","journal-title":"Drug Inf J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1161\/hc3001.092038","article-title":"Destruction of contrast microbubbles by ultrasound effects on myocardial function, coronary perfusion pressure, and microvascular integrity","volume":"104","author":"Ay","year":"2001","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00002018-200124050-00001","article-title":"Evaluation of drug-induced QT interval prolongation","volume":"24","author":"Malik","year":"2001","journal-title":"Drug Saf"},{"key":"B36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1067\/mje.2000.103865","article-title":"Premature ventricular contractions during triggered imaging with ultrasound contrast","volume":"13","author":"van der Wouw","year":"2000","journal-title":"J Am Soc Echocardiogr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.echo.2012.01.019","article-title":"The effect of definity on systemic and pulmonary hemodynamics in patients","volume":"25","author":"Wei","year":"2012","journal-title":"J Am Soc Echocardiogr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.amjcard.2013.07.026","article-title":"Effect of optison on pulmonary artery systolic pressure and pulmonary vascular resistance","volume":"112","author":"Main","year":"2013","journal-title":"Am J Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Standardized lung function testing. Official statement of the European respiratory society","volume":"6","year":"1993","journal-title":"Eur Respir J"},{"key":"B40","first-page":"937","article-title":"Nomenclature and definitions in respiratory physiology and clinical aspects of chronic lung diseases","volume":"11","author":"Denolin","year":"1975","journal-title":"Bull Physiopathol Respir"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2008.03.006","article-title":"Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 patients","volume":"51","author":"Kusnetzky","year":"2008","journal-title":"J Am Cardiol Coll"},{"key":"B42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1742-1241.1992.tb10314.x","article-title":"Assessment of reversibility in patients with chronic airflow obstruction","volume":"46","author":"Barros","year":"1992","journal-title":"Br J Clin Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/thx.42.7.487","article-title":"Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects","volume":"42","author":"Tweeddale","year":"1987","journal-title":"Thorax"},{"key":"B44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1225654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T09:47:21Z","timestamp":1690969641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1225654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":44,"alternative-id":["10.3389\/fcvm.2023.1225654"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1225654","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"article-number":"1225654"}}